Dollar Amounts
USD (Millions)
Balance sheet data in USD (millions)
Doing some research...
From 2021 through 2024 Elevance’s reported total assets rose from $97.5bn to $116.9bn — a cumulative increase of about 20% (year‑over‑year gains of roughly +5.5%, +6.0% and +7.3%). Total liabilities increased from $61.3bn to $75.5bn over the same period, a ~23% rise (notable yearly moves of +8.2%, +4.7% and +8.6%). Stockholders’ equity grew more modestly from $36.1bn to $41.3bn (~14.6% total; +0.7%, +8.3% and +5.1% by year). As a result the balance‑sheet mix shifted slightly toward higher leverage: liabilities/assets rose from ~62.9% in 2021 to ~64.6% in 2024, while equity/assets fell from ~37.0% to ~35.4%. These trends are consistent with a large health‑insurer scaling operations (assets up) while reserves and claim liabilities expand with enrollment and healthcare cost inflation. Equity growth shows retained earnings/capital accumulation but lagged the pace of liability growth, which could reflect higher claims cost, capital returned to shareholders, or targeted use of balance‑sheet financing; the 2022→2023 jump in equity suggests a stronger earnings year or lower capital actions then. The 2025 row of zeros appears to be missing data. Overall the company maintains a sizable equity base and steady asset growth, but the modest rise in leverage and faster liability growth are worth monitoring relative to underwriting margins and regulatory capital ratios.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.